227 related articles for article (PubMed ID: 20414037)
1. [Successful desensitization protocol for patients with hypersensitivity reactions caused by carboplatin].
Nishio S; Koyanagi T; Miyabe K; Kuromatsu H
Gan To Kagaku Ryoho; 2010 Apr; 37(4):731-3. PubMed ID: 20414037
[TBL] [Abstract][Full Text] [Related]
2. [Successful desensitization using cisplatin after carboplatin-associated hypersensitivity reactions in 3 cases with recurrent ovarian carcinoma].
Hosaka M; Ebina Y; Moriwaki M; Hara Y; Araki N; Todo Y; Takeda M; Watari H; Sakuragi N
Gan To Kagaku Ryoho; 2007 Sep; 34(9):1505-8. PubMed ID: 17876157
[TBL] [Abstract][Full Text] [Related]
3. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
Robinson JB; Singh D; Bodurka-Bevers DC; Wharton JT; Gershenson DM; Wolf JK
Gynecol Oncol; 2001 Sep; 82(3):550-8. PubMed ID: 11520154
[TBL] [Abstract][Full Text] [Related]
4. Carboplatin desensitization.
Choi J; Harnett P; Fulcher DA
Ann Allergy Asthma Immunol; 2004 Aug; 93(2):137-41. PubMed ID: 15328672
[TBL] [Abstract][Full Text] [Related]
5. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions.
Lee CW; Matulonis UA; Castells MC
Gynecol Oncol; 2004 Nov; 95(2):370-6. PubMed ID: 15491759
[TBL] [Abstract][Full Text] [Related]
6. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses.
Lee CW; Matulonis UA; Castells MC
Gynecol Oncol; 2005 Nov; 99(2):393-9. PubMed ID: 16054201
[TBL] [Abstract][Full Text] [Related]
7. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer.
Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC
Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
[TBL] [Abstract][Full Text] [Related]
9. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.
Ottaiano A; Tambaro R; Greggi S; Prato R; Di Maio M; Esposito G; Scala F; Barletta E; Losito S; De Vivo R; Iaffaioli VR; Pignata S
Anticancer Res; 2003; 23(4):3465-8. PubMed ID: 12926091
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.
Bolis G; Scarfone G; Giardina G; Villa A; Mangili G; Melpignano M; Presti M; Tateo S; Franchi M; Parazzini F;
Gynecol Oncol; 2001 Apr; 81(1):3-9. PubMed ID: 11277642
[TBL] [Abstract][Full Text] [Related]
12. Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions.
Broome CB; Schiff RI; Friedman HS
Med Pediatr Oncol; 1996 Feb; 26(2):105-10. PubMed ID: 8531847
[TBL] [Abstract][Full Text] [Related]
13. Carboplatin hypersensitivity: evaluation and successful desensitization protocol.
Bruchim I; Goldberg A; Fishman A; Confino-Cohen R
Immunotherapy; 2014; 6(8):905-12. PubMed ID: 25313569
[TBL] [Abstract][Full Text] [Related]
14. One year maintenance of carboplatin in patients with epithelial ovarian cancer--a phase II study.
Safra T; Kovner F; Barak N; Inbar MJ; Ron IG
Isr Med Assoc J; 2006 Jan; 8(1):27-9. PubMed ID: 16450747
[TBL] [Abstract][Full Text] [Related]
15. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management.
Hesterberg PE; Banerji A; Oren E; Penson RT; Krasner CN; Seiden MV; Wong JT
J Allergy Clin Immunol; 2009 Jun; 123(6):1262-7.e1. PubMed ID: 19501233
[TBL] [Abstract][Full Text] [Related]
16. Successful carboplatin desensitization in patients with proven carboplatin allergy.
Confino-Cohen R; Fishman A; Altaras M; Goldberg A
Cancer; 2005 Aug; 104(3):640-3. PubMed ID: 15977213
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
[TBL] [Abstract][Full Text] [Related]
18. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-26-S15-29. PubMed ID: 9346218
[TBL] [Abstract][Full Text] [Related]
19. Administration of cisplatin in three patients with carboplatin hypersensitivity: is skin testing useful?
Syrigou E; Makrilia N; Vassias A; Nikolaidis I; Xyla V; Manolopoulos L; Syrigos K
Anticancer Drugs; 2010 Mar; 21(3):333-8. PubMed ID: 20038831
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin desensitization.
Keat K; Harnett P; Fulcher DA
Ann Allergy Asthma Immunol; 2007 Nov; 99(5):468-9. PubMed ID: 18051220
[No Abstract] [Full Text] [Related]
[Next] [New Search]
